SPY312.18+4.10 1.33%
DIA263.17+5.32 2.06%
IXIC9,682.91+74.54 0.78%

Global Blood Therapeutics Highlights Data Presentations At Upcoming European Hematology Association Congress Jun. 12

Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts will be presented during the virtual edition of the 25th Annual European Hematology Association (EHA) Congress taking place June

Benzinga · 05/14/2020 13:26

Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts will be presented during the virtual edition of the 25th Annual European Hematology Association (EHA) Congress taking place June 11-14. The abstracts include a retrospective analysis of data from the landmark STOP 2 study linking higher hemoglobin levels to lower transcranial Doppler (TCD) flow velocity, a predictor of stroke risk in children with sickle cell disease (SCD), and three encore presentations of the pivotal Phase 3 HOPE Study of Oxbryta® (voxelotor). Oxbryta is the first drug approved by the U.S. Food and Drug Administration that directly inhibits sickle hemoglobin polymerization, the process that causes red blood cells to sickle and break down.

“Children with SCD have a greatly elevated risk of stroke, and the STOP 2 study provided critical insights that have informed current stroke prevention strategies. We are pleased to present data from this landmark study that further support the relationship between increased hemoglobin levels and decreased risk of stroke, as assessed by TCD flow velocity,” said Ted W. Love, M.D., president and chief executive officer of GBT. “These are important findings that support the potential for Oxbryta to have a clinically meaningful effect on stroke risk, which we are further evaluating in our HOPE-KIDS 2 post-approval confirmatory trial.”

The EHA abstracts are now available at www.ehaweb.org. Details of GBT’s poster presentations are as follows:

Friday, June 12

Session: Sickle Cell Disease
Abstract #EP1533: Correlation Between Hemoglobin Levels and Transcranial Doppler Velocities: A Retrospective STOP 2 Analysis in Children with Sickle Cell Disease
Presenter: Jenifer Voeks, Ph.D., Medical University of South Carolina
Time: 8:30 a.m. CEST

Session: Sickle Cell Disease
Abstract #EP1540: Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study
Presenter: Jo Howard, MB BChir, MRCP, FRCPath, Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London
Time: 8:30 a.m. CEST

Session: Sickle Cell Disease
Abstract #EP1534: Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study
Presenter: Russell Ware, M.D., Ph.D., Cincinnati Children’s Hospital Medical Center
Time: 8:30 a.m. CEST

Session: Sickle Cell Disease
Abstract #EP1526: Incidence of Vaso-occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or After Discontinuation: Analyses of the HOPE Study
Presenter: Elliott Vichinsky, M.D., UCSF Benioff Children’s Hospital Oakland
Time: 8:30 a.m. CEST